AstraZeneca announced on Feb. 5, 2015 that it had entered into a definitive agreement with Actavis to acquire the rights to Actavis branded respiratory business in the US and Canada for an initial consideration of $600 million upon acquisition completion and low single-digit royalties aOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.